

**REGISTERED NUMBER: 11441273 (England and Wales)**

**Unaudited Financial Statements for the Year Ended 31 December 2022**

**for**

**Crossways Pharma Limited**

**Contents of the Financial Statements  
for the Year Ended 31 December 2022**

|                                                | <b>Page</b> |
|------------------------------------------------|-------------|
| <b>Company Information</b>                     | <b>1</b>    |
| <b>Chartered Certified Accountants' Report</b> | <b>2</b>    |
| <b>Statement of Financial Position</b>         | <b>3</b>    |
| <b>Notes to the Financial Statements</b>       | <b>4</b>    |

**Crossways Pharma Limited**  
**Company Information**  
**for the Year Ended 31 December 2022**

**DIRECTORS:**

M J Doorbar  
Ms J A Cripps

**REGISTERED OFFICE:**

Rivendell Cottage  
Plastow Green  
Headley  
Thatcham  
Berkshire  
RG19 8LP

**REGISTERED NUMBER:**

11441273 (England and Wales)

**ACCOUNTANTS:**

Sherringtons  
Chartered Certified Accountants  
South Building  
Upper Farm  
Wootton St Lawrence  
Basingstoke  
Hampshire  
RG23 8PE

**Chartered Certified Accountants' Report to the Board of Directors  
on the Unaudited Financial Statements of  
Crossways Pharma Limited**

**The following reproduces the text of the report prepared for the directors in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Statement of Financial Position. Readers are cautioned that the Income Statement and certain other primary statements and the Report of the Directors are not required to be filed with the Registrar of Companies.**

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Crossways Pharma Limited for the year ended 31 December 2022 which comprise the Income Statement, Statement of Financial Position, Statement of Changes in Equity and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Association of Chartered Certified Accountants, we are subject to its ethical and other professional requirements which are detailed at <http://www.accaglobal.com/rulebook>.

This report is made solely to the Board of Directors of Crossways Pharma Limited, as a body, in accordance with our terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of Crossways Pharma Limited and state those matters that we have agreed to state to the Board of Directors of Crossways Pharma Limited, as a body, in this report in accordance with the requirements of the Association of Chartered Certified Accountants as detailed at <http://www.accaglobal.com/factsheet163>. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and its Board of Directors, as a body, for our work or for this report.

It is your duty to ensure that Crossways Pharma Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Crossways Pharma Limited. You consider that Crossways Pharma Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Crossways Pharma Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

Sherringtons  
Chartered Certified Accountants  
South Building  
Upper Farm  
Wootton St Lawrence  
Basingstoke  
Hampshire  
RG23 8PE

18 September 2023

**Statement of Financial Position  
31 December 2022**

|                                              | <b>Notes</b> | <b>2022</b><br><b>£</b> | <b>2021</b><br><b>£</b> |
|----------------------------------------------|--------------|-------------------------|-------------------------|
| <b>CURRENT ASSETS</b>                        |              |                         |                         |
| Debtors                                      | 4            | 1,031                   | (234)                   |
| Cash at bank                                 |              | <u>18,102</u>           | <u>500</u>              |
|                                              |              | 19,133                  | 266                     |
| <b>CREDITORS</b>                             |              |                         |                         |
| Amounts falling due within one year          | 5            | <u>(9,015)</u>          | <u>(601)</u>            |
| <b>NET CURRENT ASSETS/(LIABILITIES)</b>      |              | <u>10,118</u>           | <u>(335)</u>            |
| <b>TOTAL ASSETS LESS CURRENT LIABILITIES</b> |              | <u>10,118</u>           | <u>(335)</u>            |
| <b>CAPITAL AND RESERVES</b>                  |              |                         |                         |
| Called up share capital                      | 6            | 100                     | 100                     |
| Retained earnings                            |              | <u>10,018</u>           | <u>(435)</u>            |
| <b>SHAREHOLDERS' FUNDS</b>                   |              | <u>10,118</u>           | <u>(335)</u>            |

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2022.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2022 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 18 September 2023 and were signed on its behalf by:

M J Doorbar - Director

**Notes to the Financial Statements  
for the Year Ended 31 December 2022**

**1. STATUTORY INFORMATION**

Crossways Pharma Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

**2. ACCOUNTING POLICIES**

**Basis of preparing the financial statements**

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

**Turnover**

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

**Taxation**

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.

**Deferred tax**

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

**Foreign currencies**

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the statement of financial position date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

**3. EMPLOYEES AND DIRECTORS**

The average number of employees during the year was 2 (2021 - 2) .

**4. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

|               | <b>2022</b>  | <b>2021</b>  |
|---------------|--------------|--------------|
|               | <b>£</b>     | <b>£</b>     |
| Trade debtors | 1,031        | -            |
| Other debtors | -            | (234)        |
|               | <u>1,031</u> | <u>(234)</u> |

**Notes to the Financial Statements - continued  
for the Year Ended 31 December 2022**

**5. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

|                              | <b>2022</b>         | <b>2021</b>       |
|------------------------------|---------------------|-------------------|
|                              | <b>£</b>            | <b>£</b>          |
| Taxation and social security | 3,449               | 77                |
| Other creditors              | <u>5,566</u>        | <u>524</u>        |
|                              | <u><u>9,015</u></u> | <u><u>601</u></u> |

**6. CALLED UP SHARE CAPITAL**

**Allotted, issued and fully paid:**

| <b>Number:</b> | <b>Class:</b> | <b>Nominal<br/>value:</b> | <b>2022</b>       | <b>2021</b>       |
|----------------|---------------|---------------------------|-------------------|-------------------|
|                |               |                           | <b>£</b>          | <b>£</b>          |
| 100            | Ordinary      | £1                        | <u><u>100</u></u> | <u><u>100</u></u> |

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.